Variant Summary
- Also known as
- REARRANGEMENT,ALK Fusion
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 37
Evidence Level Distribution
Level A: 11Level B: 15Level C: 9Level E: 2
Evidence Items
Showing CIViC evidence rows where gene = v::ALK and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Brigatinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib,Crizotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Anaplastic Large Cell Lymphoma | Crizotinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Anaplastic Large Cell Lymphoma | Crizotinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 4 |
| C | Diagnostic | Supports | Positive | Inflammatory Myofibroblastic Tumor | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Brigatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Lorlatinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Inflammatory Myofibroblastic Tumor | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Inflammatory Myofibroblastic Tumor | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Crizotinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Cancer | Entrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Anaplastic Thyroid Carcinoma | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Anaplastic Large Cell Lymphoma | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Inflammatory Myofibroblastic Tumor | Crizotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pemetrexed | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Retaspimycin Hydrochloride | 2 |
| C | Predictive | Supports | Sensitivity/Response | Diffuse Large B-cell Lymphoma | Crizotinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Vagina Sarcoma | Crizotinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Epithelioid Inflammatory Myofibroblastic Sarcoma | Crizotinib | 2 |
| E | Predictive | Supports | Sensitivity/Response | Colorectal Adenocarcinoma | Crizotinib | 1 |
| E | Predictive | Supports | Sensitivity/Response | Breast Cancer | Crizotinib | 1 |